Literature DB >> 23243356

Is 68Ga-DOTATATE the answer in lung carcinoid? : Case report and review of literature.

Amit Bhoil1, Bhagwant R Mittal, Shankaramurthy Gayana, Raghava Kashyap, Anish Bhattacharya, Navneet Singh.   

Abstract

Carcinoid tumors are rich in somatostatin receptors and show high uptake of radiotracer on octreotide scintigraphy. 68Ga-DOTATATE could be of great help at initial staging and during follow-up of these patients. We describe a patient with avid 68Ga-DOTATATE and poor F18-FDG uptake.

Entities:  

Keywords:  68Ga-DOTATATE; FDG; Lung carcinoid; PET/CT

Year:  2012        PMID： 23243356      PMCID： PMC3519028          DOI： 10.4103/0970-2113.102839

Source DB:  PubMed          Journal:  Lung India        ISSN： 0970-2113


  13 in total

Review 1.  Carcinoid tumors.

Authors:  M H Kulke; R J Mayer
Journal:  N Engl J Med       Date:  1999-03-18       Impact factor: 91.245

2.  Benign tumors of the tracheobronchial tree: CT-pathologic correlation.

Authors:  Jeong Min Ko; Jung Im Jung; Seog Hee Park; Kyo Young Lee; Myung Hee Chung; Myeong Im Ahn; Ki Jun Kim; Yo Won Choi; Seong Tai Hahn
Journal:  AJR Am J Roentgenol       Date:  2006-05       Impact factor: 3.959

3.  68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Authors:  Alexander R Haug; Christoph J Auernhammer; Björn Wängler; Gerwin P Schmidt; Christopher Uebleis; Burkhard Göke; Paul Cumming; Peter Bartenstein; Reinhold Tiling; Marcus Hacker
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

4.  What can gallium-68 PET add to receptor and molecular imaging?

Authors:  Adil Al-Nahhas; Zarni Win; Teresa Szyszko; Aviral Singh; Sameer Khan; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

5.  Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.

Authors:  K L Laitinen; Y Soini; J Mattila; P Pääkkö
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

6.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

7.  Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

Authors:  Irfan Kayani; Jamshed B Bomanji; Ashley Groves; Gerard Conway; Sveto Gacinovic; Thida Win; John Dickson; Martyn Caplin; Peter Joseph Ell
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

8.  Functional imaging in differentiating bronchial masses: an initial experience with a combination of (18)F-FDG PET-CT scan and (68)Ga DOTA-TOC PET-CT scan.

Authors:  Arvind Kumar; Tarun Jindal; Roman Dutta; Rakesh Kumar
Journal:  Ann Nucl Med       Date:  2009-09-29       Impact factor: 2.668

9.  Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications.

Authors:  Semin Chong; Kyung Soo Lee; Byung-Tae Kim; Joon Young Choi; Chin A Yi; Myung Jin Chung; Dae-Kun Oh; Ji-Young Lee
Journal:  AJR Am J Roentgenol       Date:  2007-05       Impact factor: 3.959

10.  A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.

Authors:  Irfan Kayani; Brendon G Conry; Ashley M Groves; Thida Win; John Dickson; Martyn Caplin; Jamshed B Bomanji
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.